L Mauriac

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.

D B Evans, M. Ellis, Baljit Singh, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer.

L Biganzoli, M. Piccart, M. Nooij, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.